Orange Book product · Brand (NDA)
REYVOW
LASMIDITAN SUCCINATE
At a glance
Jan 31, 2020
Approved
Brand (NDA)
Application
Not listed
TE code
4
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Jan 31, 2020
6 yr 6 mo ago
Today
Patent 7423050 expires
Listed drug substance patent expiration.
Feb 17, 2028
in 1 yr 8 mo
Patent 12257246 expires
Listed method-of-use patent (U-2718) expiration.
Jul 07, 2030
in 4 yr 1 mo
Patent 11053214 expires
Listed drug substance patent expiration.
Dec 05, 2037
in 11 yr 8 mo
Patent 12071423 expires
Listed drug product patent expiration.
Jul 06, 2040
in 14 yr 3 mo
Pharmaceutical detail
Active ingredient
LASMIDITAN SUCCINATE
Strength
EQ 50MG BASE
Dosage form
TABLET
Route
ORAL
TE code
Not listed
Application
NDA 211280
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
No
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
Listed patents (4)
| Patent | Expires | In | Type |
|---|---|---|---|
| 7423050 | Feb 17, 2028 | in 1 yr 8 mo | SubstanceProductU-1719 |
| 12257246 | Jul 07, 2030 | in 4 yr 1 mo | U-2718 |
| 11053214 | Dec 05, 2037 | in 11 yr 8 mo | SubstanceProductU-1719 |
| 12071423 | Jul 06, 2040 | in 14 yr 3 mo | Product |
